| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44041843 | HTLV-1 | ENSG00000140443.15 | protein_coding | IGF1R | Yes | No | 3480 | C9J5X1 P08069 |
| TVIS44047281 | HTLV-1 | ENSG00000140443.15 | protein_coding | IGF1R | Yes | No | 3480 | C9J5X1 P08069 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | IGF1R |
|---|---|
| DrugBank ID | DB11840 |
| Drug Name | Dalotuzumab |
| Target ID | BE0000858 |
| UniProt ID | P08069 |
| Regulation Type | antibody |
| PubMed IDs | 25290091 |
| Citations | Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE: A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7. |
| Groups | Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
